The aim of this trial is to test the safety and tolerability of macrophage cell therapy in acute liver injury following paracetamol overdose. Macrophage Therapy For Acute Liver Injury (MAIL) Trial: A Phase 1 Randomised, Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages (AAM) in Patients with Paracetamol-induced Acute Liver Injury. Image Chief Investigator: Professor James Dear Number and location of participating sites (by region/ country): Single Centre, Edinburgh Royal Infirmary ISRCTN number: ISRCTN12637839 Funder: Medical Research Council Start and End date Of grant award: 01 December 2022 - 30 November 2025 Of recruitment: 01 September 2023 - 30 April 2025 Current Status: Recruiting Email: MAIL.Trial@ed.ac.uk Sponsor: University of Edinburgh and NHS Lothian - https://www.accord.scot/ Chief Investigator: Professor James Dear, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, james.dear@ed.ac.uk Trial Manager: Anna Heye, Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5‒7 Little France Road, Edinburgh BioQuarter ‒ Gate 3, Edinburgh EH16 4UX MAIL.Trial@ed.ac.uk UK GDPR Privacy Statement: Contained within the patient information booklet ECTU involvement: Trial Management, Statistics, Database This article was published on 2024-09-24
